Drug Profile
Tiprelestat - tiakis Biotech
Alternative Names: ElafinLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Proteo Biotech
- Developer Duke University; MiGenTra Egypt; Rhein Minapharm Biogenetics; SRI International; Stanford University; tiakis Biotech
- Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Recombinant proteins
- Mechanism of Action Leucocyte elastase inhibitors; Myeloblastin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID-19 respiratory infection; Myocardial reperfusion injury; Postoperative inflammation
- Phase I Pulmonary arterial hypertension
- No development reported Lung disorders; Lung transplant rejection
Most Recent Events
- 28 Nov 2023 Phase-I clinical development in Pulmonary arterial hypertension (In volunteers, In adults) is ongoing in USA (SC) (tiakis Biotech pipeline, November 2023)
- 28 Nov 2023 tiakis Biotech plans a phase II trial in Pulmonary arterial hypertension (tiakis Biotech pipeline, November 2023)
- 30 Aug 2023 Phase-II development is ongoing in Egypt (IV) (MiGenTra Egypt pipeline, August 2023)